Drugs Controller General of India approves New anti-COVID drug 2-deoxy-D-glucose (2-DG) in INDIA
📌𝐅𝐨𝐥𝐥𝐨𝐰 𝐨𝐧 𝐈𝐧𝐬𝐭𝐚𝐠𝐫𝐚𝐦:- / drgbhanuprakash 📌𝗝𝗼𝗶𝗻 𝗢𝘂𝗿 𝗧𝗲𝗹𝗲𝗴𝗿𝗮𝗺 𝗖𝗵𝗮𝗻𝗻𝗲𝗹 𝗛𝗲𝗿𝗲:- https://t.me/bhanuprakashdr 📌𝗦𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝗧𝗼 𝗠𝘆 𝗠𝗮𝗶𝗹𝗶𝗻𝗴 𝗟𝗶𝘀𝘁:- https://linktr.ee/DrGBhanuprakash DCGI approves New anti-COVID drug 2-deoxy-D-glucose (2-DG) developed by DRDO for emergency use. Today i am going to talk about the latest update regarding the treatment of covid 19. the drugs controller general of india that is DCGI has granted permission for emergency use of anti-covid19 therapeutic application of the drug 2-deoxy D-glucose known as 2dg which is developed by the institute of nuclear medicine and allied sciences known as Inmass and the lab of defense research and development organization DRDO in collaboration with Dr reddy's laboratories Hyderabad the drug comes in powder form in sachet which is taken orally by dissolving it in water in the latest press release issued on Saturday the ministry of defense said that as per the order emergency use of this particular drug as adjuvant therapy is used in moderate to severe covid 19 patients is permitted and the press release also added that being a generic molecule and analog of glucose it can be easily produced and made available in plenty in the country. As i already mentioned earlier that the drug comes in powder form in sachet which is taken orally by dissolving it in water and this particular drug is going to accumulate in the virus infected cells and prevents the virus growth by stopping the viral protein synthesis and energy production so its selective accumulation in vi-rally infected cells makes this drug particularly unique when compared to that of any of the drugs which are present in the market and the clinical trial results have shown that this particular molecule helps in foster recovery of hospitalized patients and reduces supplemental oxygen dependence that is what they have explained in the press release it further said that higher proportion of patients who are treated with this particular drug that is 2DG showed RTPCR negative conversion in COVID 19 patients and the drug will be of immense benefit to the people suffering from COVID 19 said by the ministry and if you see the history of this particular drug and the clinical trials in April 2020 that is during the first wave of the pandemic inmass, DRDO scientists conducted a laboratory experiment with the help of the center for cellular and molecular biology that is CCMB Hyderabad and found that this molecule works effectively against SARS corona virus 2 and inhibits the viral growth therefore the DCGI permitted phase 2 clinical trials of 2DG in COVID 19 patients in may 2020. The DRDO along with its industry partner DRL Hyderabad started the clinical trials to test the safety as well as efficacy of the drug in COVID 19 patients and in phase 2 trials conducted during may to October 2020 the drug was found to be safe in COVID 19 patients and showed it led to a significant improvement in their recovery also and phase 2a was conducted in approximately 6 hospitals and phase 2b clinical trials was conducted at 11 hospitals all over the country and phase 2 trial was conducted approximately on 110 patients in efficacy trends if you notice patients treated with 2DG showed faster symptomatic cure than the standard of care on various endpoints and a significantly favorable trend was seen in terms of median time to achieving normalization of specific vital science parameters when compared to standard of care and based on the successful results the DCGI further permitted phase 3 clinical trials in November 2020 and the phase 3 clinical trials was conducted approximately on 220 patients that is between December 2020 to march 2021 at 27 COVID 19 hospitals in the states of Delhi, Uttar pradesh, west bengal, Gujarat, Rajasthan, Maharashtra, Andhra pradesh, Telangana, Karnataka and Tamil Nadu and the detailed data of the phase 3 clinical trial was presented to the DCGI and in the 2DG arm significantly higher proportion of the patients improved symptomatically and became free from supplemental oxygen dependence by day 3 in comparison to standard of care indicating an early relief from oxygen therapy or oxygen dependence and the same that is similar trend was also observed in the patient's age more than 65 years that is what they have noted in the release and this is pretty much good news for everyone and let's see how this drug is going to be a miraculous journey in the COVID 19 treatment. #2DG #dcgiapproves2dg #2dganticoviddrug #drug2deoxyDglucose #newanticoviddrug #anticoviddrug2DG #covid19india #covidinindia #covidtreatment #coronavirusdiseasedrugs #anticoviddrugs #covidtreatmentinindia
